Seres Therapeutics, Inc. - COMMON STOCK (MCRB) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q2 2025

Type / Class: Equity / COMMON STOCK
Symbol: MCRB on Nasdaq
Shares outstanding: 170,403,883
Price per share: $0.37
Price from insider filings: $0.37

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Seres Therapeutics, Inc. - COMMON STOCK (MCRB) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	13%		$12,868,901		21,811,697		FMR LLC	31 Dec 2024

Institutional Holders of Seres Therapeutics, Inc. - COMMON STOCK (MCRB) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q2	0	$0	-$42,948,667	$0	$0	$0.37	0
2025 Q1	61,356,952	$42,953,245	-$1,247,521	$37,103	$72,171	$0.70	59
2024 Q4	63,077,898	$52,465,502	-$351,303	$189,334	$2,453,586	$0.83	69
2024 Q3	63,393,718	$59,956,736	-$4,726,686	$445,772	$286,923	$0.95	74
2024 Q2	69,127,923	$50,036,502	-$12,236,250	$335,801	$86,060	$0.72	90
2024 Q1	85,696,041	$66,338,945	-$8,845,429	$367,010	$28,564	$0.77	95
2023 Q4	40,532	$56,745				$1.40	1
2023 Q3	107,360,553	$255,517,093	-$22,473,748	$846,192	$1,180,718	$2.38	132
2023 Q2	112,314,465	$538,060,840	+$33,901,765	$2,821,138	$3,314,515	$4.79	138
2023 Q1	104,744,918	$593,889,758	-$2,076,554	$1,557,549	$1,586,466	$5.67	122
2022 Q4	105,075,197	$588,196,500	+$1,169,232	$679,840	$1,182,160	$5.60	123
2022 Q3	98,057,313	$628,741,787	+$109,067,321	$828,000	$1,320,000	$6.42	112
2022 Q2	89,293,605	$306,198,091	+$47,109,617	$627,000	$621,000	$3.43	115
2022 Q1	75,367,088	$536,586,498	-$11,242,283	$1,568,000	$2,894,000	$7.12	124
2021 Q4	76,905,919	$640,571,364	-$21,544,871	$2,244,000	$2,885,000	$8.33	138
2021 Q3	79,483,123	$554,239,273	-$220,727,402	$1,608,000	$2,839,000	$6.96	125
2021 Q2	66,556,096	$1,580,193,279	-$104,740,342	$5,026,000	$40,217,000	$23.85	138
2021 Q1	74,773,001	$1,539,622,666	+$74,862,492	$3,913,000	$26,227,000	$20.59	147
2020 Q4	71,198,566	$1,746,079,811	+$153,236,710	$5,216,000	$16,273,000	$24.50	141
2020 Q3	85,849,191	$2,425,962,273	+$414,501,115	$14,006,000	$67,166,000	$28.31	110
2020 Q2	71,964,573	$342,248,262	+$20,299,029	$2,855,000	$3,200,000	$4.76	90
2020 Q1	65,512,788	$233,777,175	+$6,970,734	$0		$3.57	69
2019 Q4	65,931,868	$227,460,925	+$4,745,100	$144,000	$0	$3.45	74
2019 Q3	64,289,841	$257,783,726	+$14,721,508	$156,000	$1,102,000	$4.01	69
2019 Q2	61,496,149	$197,770,021	+$89,305,490	$230,000	$1,447,000	$3.22	82
2019 Q1	33,390,092	$229,390,136	+$13,124,369	$230,000	$102,000	$6.87	74
2018 Q4	29,448,724	$133,105,876	-$2,132,681	$119,000	$0	$4.52	62
2018 Q3	31,840,629	$241,689,503	+$1,353,199	$93,000	$158,000	$7.59	66
2018 Q2	31,799,503	$273,574,153	-$2,874,818	$139,000	$398,000	$8.60	74
2018 Q1	32,343,237	$237,397,127	+$909,785	$125,000	$686,000	$7.34	76
2017 Q4	32,092,188	$325,414,128	+$13,232,583	$675,000	$881,000	$10.14	84
2017 Q3	18,094,780	$290,387,662	+$9,431,326	$8,803,000	$1,766,000	$16.04	77
2017 Q2	28,147,214	$318,071,628	-$4,532,571	$386,000	$1,240,000	$11.30	70
2017 Q1	28,812,166	$324,711,136	-$6,106,130	$276,000	$955,000	$11.27	77
2016 Q4	31,110,398	$307,998,792	-$7,898,896	$539,000	$202,000	$9.90	89
2016 Q3	31,168,555	$383,056,907	-$53,572,954	$2,545,000	$631,000	$12.29	92
2016 Q2	18,811,127	$546,514,562	+$53,773,549	$4,419,000	$1,142,000	$29.05	88
2016 Q1	30,947,144	$821,904,418	+$43,113,422	$1,437,000	$930,000	$26.56	76
2015 Q4	15,203,165	$533,480,616	+$58,408,622	$2,148,000	$3,763,000	$35.09	66
2015 Q3	13,564,810	$401,454,187	+$65,134,045		$1,583,000	$29.64	58
2015 Q2	11,381,595	$471,486,114	+$461,249,860			$41.50	45